Physician profile
Manuel Weiskopf
NPI 1275557100
$402.80
in general payments reported to CMS, 2019-2025
9 companies · $188 in 2025
The $188 reported for 2025 was more than what 80% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.51 · 2020: $12.50 · 2021: $17.45 · 2023: $49.43 · 2024: $48.61 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $140.95 | 2025 | Fisher & Paykel Healthcare |
| Mallinckrodt Enterprises LLC | $49.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.61 | 2024 | Entyvio |
| Haemonetics Corporation | $47.35 | 2025 | Teg6s Hemostasis System |
| Janssen Biotech, INC. | $45.57 | 2020-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.84 | 2019 | |
| Cook Medical LLC | $17.46 | 2019 | |
| Acacia Pharma INC | $17.45 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.36 | 2023 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Weiskopf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.